Improved survival in multiple myeloma and the impact of novel therapies.

By Shaji K. Kumar, S. Rajkumar, A. Dispenzieri, M. Lacy, S. Hayman, F. Buadi, S. Zeldenrust, D. Dingli, S. Russell, J. Lust and 3 more. Blood, 2008

2,308 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010, background): “The introduction of the proteasome inhibitor bortezomib and the immunomodulatory drugs thalidomide and lenalidomide has been associated with improved survival.(4,5) Combinations of bortezomib or lenalidomide with conventional anti-MM drugs have demonstrated very high overall response rates and quali”
Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients (2013, methodology): “Patients were considered to have high risk disease if FISH studies demonstrated one of the following abnormalities: t(4;14), t(14;16), t(14;20), or loss of p53 gene locus (del 17p or monosomy 17) in the absence of any trisomies.”
Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines. (2009, background): “Considerable progress has been made during the past decade in understanding the basic biology of this disease and in development of more effective therapies.(3) One of the most important advances in the field has been the appreciation of the genetic heterogeneity that underlies this disease and its ”
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. (2015, neutral): “Pyrexia 13 (43) 0 7 (17) 1 (2) 20 (28) 1 (1)”